CGONCG Oncology, Inc.

1. Aug 6, 2026On August 6, 2026, the Company filed Amendment No. 2 to Prospectus (the “Amendment No. 2”) with the Securities and Exchange Commission (the “SEC”) for the offer and sale of shares of its common stock, par value $0.0001 per share (the “Shares”), pursuant to that certain Open Market Sale Agreement, dated March 28, 2025 …Earnings release · Form 8-K
2. May 26, 2026Bellete Separation On May 20, 2026, CG Oncology, Inc. (the “Company”) and Ambaw Bellete, the Company’s President & Chief Operating Officer of the Company, agreed to his separation from the Company to be effective June 30, 2026.Director or officer change · Form 8-K
3. Apr 13, 2026Appointment of Chief Financial Officer On April 13, 2026, CG Oncology, Inc. (the “Company”) appointed Jim DeTore as the Company’s Chief Financial Officer.Director or officer change · Form 8-K
4. Feb 27, 2026CG Oncology Reports 2025 Year End Financial Results and Provides Business Updates.Earnings release · press release
5. Jan 13, 2026On January 13, 2026, CG Oncology, Inc. (the “Company”) filed Amendment No. 1 to Prospectus (the “Amendment”) with the Securities and Exchange Commission (the “SEC”) for the offer and sale of shares of its common stock, par value $0.0001 per share, having an aggregate offering price of up to $550,000,000 (the …Other event · Form 8-K
6. Jan 9, 2026On January 9, 2026, the Company announced an expedited timeline for the topline data readout now expected in the first half of 2026 for the Phase 3 PIVOT-006 clinical trial comparing adjuvant intravesical cretostimogene grenadenorepvec versus surveillance in patients with intermediate-risk non-muscle invasive bladder …Regulation FD disclosure · Form 8-K
7. Nov 26, 2025Appointment of Christina Rossi to the Board of Directors On November 22, 2025, the Board of Directors (the “Board”) of CG Oncology, Inc. (the “Company”), upon the recommendation of the Nominating and Corporate Governance Committee of the Board, appointed Christina Rossi to the Company’s Board, effective November 24 …Director or officer change · Form 8-K
8. Nov 14, 2025Resignation of Principal Financial and Accounting Officer On November 10, 2025, Robert Lapetina, interim principal financial and accounting officer of CG Oncology, Inc. (the “Company”) delivered to the Company a notice of resignation from his position as interim principal financial and accounting officer of the Company.Director or officer change · Form 8-K
9. Nov 14, 2025CG Oncology Reports Third Quarter 2025 Financial Results and Provides Business Updates.Earnings release · press release
10. Sep 9, 2025Attacking Bladder Cancer for a Better Tomorrow™.Regulation FD disclosure · press release

Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.